Immunoglobulin G2a, anti-(human neuregulin receptor HER3) (human monoclonal MM-121 heavy chain), disulfide with human monoclonal MM-121 λ-chain, dimer (ACI)

Carotuximab

Anifrolumab

Ozanezumab

Abciximab

Immunoglobulin G1, anti-(Clostridium difficile toxin B) (human monoclonal γ-chain), disulfide with human monoclonal κ-chain, dimer (ACI)

Evolocumab

Carboxyfluorescein succinimidyl ester

Tregalizumab

Narnatumab

Sirukumab

2H-Indol-2-one, 1,3-dihydro-5-methoxy-3-[[3-[(1E)-2-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]ethenyl]-1H-indazol-6-yl]methylene]-, hydrochloride (1:2) (ACI)

Atinumab

DNA, d(P-thio)(T-C-C-T-G-G-C-G-G-G-G-A-A-G-T) (ACI)

Crenezumab

Methyl [(1R,4Z,8S,13E)-8-[[2-O-[4-(acetylethylamino)-2,4-dideoxy-3-O-methyl-α-L-threo-pentopyranosyl]-4,6-dideoxy-4-[[[2,6-dideoxy-4-S-[4-[(6-deoxy-3-O-methyl-α-L-mannopyranosyl)oxy]-3-iodo-5,6-dimethoxy-2-methylbenzoyl]-4-thio-β-D-ribo-hexopyranosyl]oxy]amino]-β-D-glucopyranosyl]oxy]-1-hydroxy-13-[2-(methyltrithio)ethylidene]-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl]carbamate (ACI)

Euphorbia factor L7a

Tralokinumab

Girentuximab

Solanezumab